Monday, July 15, 2024

CATEGORY

Clinical Researches

MIRA Pharmaceuticals Announces Promising Results for MIRA-55 in Preclinical Tests

MIRA Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, has revealed promising preclinical results for its innovative oral pharmaceutical marijuana analog, MIRA-55. The new data substantiates...

Insulin Delivery Technology: Modular Medical and Gubra Study Personalized Metabolic Therapy

Modular Medical, a pioneering company in insulin delivery technology, has announced an exciting new proof-of-concept study in collaboration with Gubra A/S. This study will...

Antibiotic Use Reduced by Over-the-Counter Nasal Sprays, Study Finds

Antibiotic use is reduced by over-the-counter nasal sprays, which are effective at lessening the symptoms and duration of flu and colds, especially in at-risk...

Fibromyalgia Digital Therapy: Swing Publishes Promising Phase III Data

Fibromyalgia management has seen a breakthrough as Swing Therapeutics has recently published positive results from its Phase III trial of Stanza, a digital therapeutic...

Obesity Treatment Breakthrough: Study Finds Tirzepatide Outperforms Semaglutide in Weight Loss

In a groundbreaking study, researchers have discovered that the diabetes medication tirzepatide significantly outperforms semaglutide in promoting weight loss among adults with overweight or...

Machine Learning Enhances Prognostic Accuracy for Liver Cancer Treatment

The promise of machine learning (ML) in healthcare continues to expand, now reaching the critical area of liver cancer treatment. A groundbreaking study by...

Liver Injury Risks Highlighted in New Study Revealing High-Risk Medications

Medical researchers have uncovered crucial insights into medications that pose a significant risk of severe acute liver injury (ALI). By leveraging real-world data from...

Obesity Treatment: Sun Pharma’s GL0034 (Utreglutide) Demonstrates Significant Weight Loss and Metabolic Benefits in ADA Presentation

Obesity treatment has shown promising results in a Phase 1 multiple ascending-dose study of GL0034 (Utreglutide), a novel GLP-1 receptor agonist, as announced by...

Antibody-Drug Conjugates Data Across Multiple Indications Presented by AbbVie at ASCO 2024

Antibody-drug conjugates (ADCs) ABBV-400 and ABBV-706 were the focus of new data presented by AbbVie at this year's American Society of Clinical Oncology (ASCO)...

Multiple Myeloma Patients Show Promising Survival Rates with Pfizer’s ELREXFIO™ in Phase 2 Study

Multiple myeloma patients with heavily pretreated relapsed or refractory disease were the focus of Pfizer Inc.'s announcement detailing overall survival (OS) results from the...

Latest news